Intrapulmonary Pharmacokinetics of Lascufloxacin in Healthy Adult Volunteers

Author:

Furuie Hidetoshi1,Tanioka Sayoko2,Shimizu Keiko3,Manita Shigeru3,Nishimura Masaharu4,Yoshida Hisao2

Affiliation:

1. Osaka Pharmacology Clinical Research Hospital, Osaka, Japan

2. Kyorin Pharmaceutical Co., Ltd., Tokyo, Japan

3. Watarase Research Center, Kyorin Pharmaceutical Co., Ltd., Tochigi, Japan

4. Department of Respiratory Medicine, Faculty of Medicine (and Graduate School of Medicine), Hokkaido University, Sapporo, Japan

Abstract

ABSTRACT This study was performed to investigate the intrapulmonary penetration of lascufloxacin in humans. Thirty healthy adult male Japanese subjects, allocated into five groups, received lascufloxacin in a single oral dose of 75 mg. Bronchoalveolar lavage and blood sampling were performed simultaneously in each subject at 1, 2, 4, 6, or 24 h after administration, and lascufloxacin concentrations in plasma, epithelial lining fluid, and alveolar macrophages were determined. Lascufloxacin was rapidly distributed to the epithelial lining fluid with a time to maximum drug concentration ( T max ) of 1 h, which was identical to that in plasma. The maximum concentration of drug ( C max ) values in plasma, epithelial lining fluid, and alveolar macrophages were 0.576, 12.3, and 21.8 μg/ml, respectively. The corresponding area under the concentration-time curve from 0 to 24 h (AUC 0–24 ) values were 7.67, 123, and 325 μg · h/ml. The mean drug concentrations in the epithelial lining fluid and alveolar macrophages were much higher than those in plasma at all time points examined, and the average site-to-free plasma concentration ratios fell within the ranges of 57.5 to 86.4 and 71.0 to 217, respectively. Drug levels in epithelial lining fluid and alveolar macrophages exceeded the MIC 90 values for common respiratory pathogens. (This study was registered at JAPIC under registration number JapicCTI-142547.)

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Reference24 articles.

1. In Vitro Activities and Spectrum of the Novel Fluoroquinolone Lascufloxacin (KRP-AM1977)

2. Totsuka K, Odajima M, Nakauchi M, Sesoko S, Nakashima M. 2016. Phase I study to determine the safety and pharmacokinetics (PK) of single and multiple oral doses of lascufloxacin (AM-1977) in healthy subjects, abstr SUNDAY-467. Abstr ASM Microbe, 16 to 20 June 2016, Boston, MA.

3. Kishii R, Yamamuro N, Yamaguchi Y, Abukawa H, Takei M. 2016. In vivo bactericidal activity of lascufloxacin (AM-1977), a newly developed fluoroquinolone, against mouse pulmonary infection model caused by Streptococcus pneumoniae, abstr SUNDAY-471. Abstr ASM Microbe, 16 to 20 June 2016, Boston, MA.

4. Totsuka K, Odajima M, Nakauchi M, Sesoko S, Nakashima M. 2016. Phase I study to determine the safety and pharmacokinetics (PK) of single and multiple intravenous infusion of lascufloxacin (AM-1977) in healthy subjects, abstr SUNDAY-470. Abstr ASM Microbe, 16 to 20 June 2016, Boston, MA.

5. Pulmonary disposition of antimicrobial agents: methodological considerations

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3